TWI589294B - 抗微生物性化合物及其製造與使用方法 - Google Patents

抗微生物性化合物及其製造與使用方法 Download PDF

Info

Publication number
TWI589294B
TWI589294B TW099135283A TW99135283A TWI589294B TW I589294 B TWI589294 B TW I589294B TW 099135283 A TW099135283 A TW 099135283A TW 99135283 A TW99135283 A TW 99135283A TW I589294 B TWI589294 B TW I589294B
Authority
TW
Taiwan
Prior art keywords
group
alkyl
pharmaceutically acceptable
tautomer
nitrogen
Prior art date
Application number
TW099135283A
Other languages
English (en)
Chinese (zh)
Other versions
TW201125564A (en
Inventor
艾琳 杜菲
阿修克 巴塔查傑
哈德溫 歐道德
馬可 迪凡
杜揚鳴
珊卓 辛尼塔
唐元清
布萊恩 溫伯利
Original Assignee
梅林塔療法公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 梅林塔療法公司 filed Critical 梅林塔療法公司
Publication of TW201125564A publication Critical patent/TW201125564A/zh
Application granted granted Critical
Publication of TWI589294B publication Critical patent/TWI589294B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
    • A61B5/6846—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive
    • A61B5/6847—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be brought in contact with an internal body part, i.e. invasive mounted on an invasive device
    • A61B5/6862—Stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Materials For Medical Uses (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW099135283A 2009-10-16 2010-10-15 抗微生物性化合物及其製造與使用方法 TWI589294B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25247809P 2009-10-16 2009-10-16
US31428710P 2010-03-16 2010-03-16
US35820110P 2010-06-24 2010-06-24

Publications (2)

Publication Number Publication Date
TW201125564A TW201125564A (en) 2011-08-01
TWI589294B true TWI589294B (zh) 2017-07-01

Family

ID=43876906

Family Applications (8)

Application Number Title Priority Date Filing Date
TW099135283A TWI589294B (zh) 2009-10-16 2010-10-15 抗微生物性化合物及其製造與使用方法
TW099135286A TW201125566A (en) 2009-10-16 2010-10-15 Antimicrobial compounds and methods of making and using the same
TW106131448A TW201825495A (zh) 2009-10-16 2010-10-15 抗微生物性化合物，及製法及其用途
TW104131806A TWI621439B (zh) 2009-10-16 2010-10-15 抗微生物性化合物及其製造與使用方法
TW099135287A TWI612048B (zh) 2009-10-16 2010-10-15 抗微生物性化合物，及製法及其用途
TW104135849A TWI618707B (zh) 2009-10-16 2010-10-15 抗微生物性化合物，及製法及其用途
TW106101234A TW201726630A (zh) 2009-10-16 2010-10-15 抗微生物性化合物及其製造與使用方法
TW106102658A TWI629277B (zh) 2009-10-16 2010-10-15 抗微生物性化合物，及製法及其用途

Family Applications After (7)

Application Number Title Priority Date Filing Date
TW099135286A TW201125566A (en) 2009-10-16 2010-10-15 Antimicrobial compounds and methods of making and using the same
TW106131448A TW201825495A (zh) 2009-10-16 2010-10-15 抗微生物性化合物，及製法及其用途
TW104131806A TWI621439B (zh) 2009-10-16 2010-10-15 抗微生物性化合物及其製造與使用方法
TW099135287A TWI612048B (zh) 2009-10-16 2010-10-15 抗微生物性化合物，及製法及其用途
TW104135849A TWI618707B (zh) 2009-10-16 2010-10-15 抗微生物性化合物，及製法及其用途
TW106101234A TW201726630A (zh) 2009-10-16 2010-10-15 抗微生物性化合物及其製造與使用方法
TW106102658A TWI629277B (zh) 2009-10-16 2010-10-15 抗微生物性化合物，及製法及其用途

Country Status (10)

Country Link
JP (6) JP2016121171A (enExample)
KR (3) KR20120099435A (enExample)
CN (5) CN104628729B (enExample)
AR (3) AR080559A1 (enExample)
EA (1) EA201500913A1 (enExample)
MY (2) MY161870A (enExample)
NZ (2) NZ713357A (enExample)
PH (1) PH12012500732A1 (enExample)
SG (3) SG10201406631TA (enExample)
TW (8) TWI589294B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI621439B (zh) * 2009-10-16 2018-04-21 梅林塔療法公司 抗微生物性化合物及其製造與使用方法
US11999739B2 (en) 2016-05-06 2024-06-04 BioVersys AG Antimicrobials methods of making and using the same

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201270568A1 (ru) 2009-10-16 2012-11-30 Риб-Экс Фармасьютикалз, Инк. Антимикробные композиции и способы их получения и применения
NZ599290A (en) 2009-10-16 2014-10-31 Melinta Therapeutics Inc Antimicrobial compounds and methods of making and using the same
MY173518A (en) * 2011-04-15 2020-01-30 Melinta Therapeutics Inc Antimicrobial compounds and methods of making and using the same
SG10201801956SA (en) 2013-09-09 2018-04-27 Melinta Therapeutics Inc Antimicrobial compounds and methods of making and using the same
EP3038623A4 (en) 2013-09-09 2017-04-19 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
BR112017019349A2 (pt) 2015-03-11 2018-06-05 Melinta Therapeutics Inc compostos antimicrobianos e métodos de fabricação e uso dos mesmos

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980781A (en) * 1966-03-31 1976-09-14 Imperial Chemical Industries Limited Fungicidal composition and method containing 2-amino-pyrimidines
US3673184A (en) * 1970-09-02 1972-06-27 Dainippon Pharmaceutical Co Certain 2-substituted-5,8-dihydro-5-oxopyrido{8 2,3-d{9 pyrimidine-6-carboxylic acid derivatives
EP0067610A1 (en) * 1981-06-16 1982-12-22 Beecham Group Plc Penicillins, a process for their preparation and compositions containing them
ZA835684B (en) * 1982-08-27 1985-03-27 Roussel Uclaf Imidazo(1,2-a)pyrimidines
IT1197876B (it) * 1986-10-15 1988-12-21 Pharmachim Engineering Srl Procedimento per la preparazione dell'acido 5,8-diidro-8-etil-5-osso-2-(1-piperazinil)pirido(2,3-d)pirimidin-6-carbossilico
JP2549931B2 (ja) * 1990-01-12 1996-10-30 株式会社大塚製薬工場 ピリミドベンズイミダゾール誘導体
JP2991382B2 (ja) * 1990-07-18 1999-12-20 大日本製薬株式会社 縮合三環式化合物およびその塩
US5208141A (en) * 1990-10-09 1993-05-04 Konica Corporation Silver halide color photographic light-sensitive material
JP2811230B2 (ja) * 1990-10-17 1998-10-15 コニカ株式会社 新規な写真用カプラー
US6451968B1 (en) * 1991-05-24 2002-09-17 Isis Pharmaceuticals, Inc. Peptide nucleic acids
US5434257A (en) * 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
US5646163A (en) * 1992-10-30 1997-07-08 The Procter & Gamble Company Quinolone 5-(N-heterosubstituted amino) antimicrobials
IT1263804B (it) * 1993-01-22 1996-09-03 Luso Farmaco Inst Derivati pirimidinonici fusi con eterocicli azotati ad attivita' a ii antagonista
PL174704B1 (pl) * 1993-05-12 1998-09-30 Du Pont Nowe 4(3H)-chinazolinony i środek grzybobójczy do zwalczania mączniaka pszenicy
US5502177A (en) * 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5668127A (en) * 1995-06-26 1997-09-16 Pathogenesis Corporation Nitroimidazole antibacterial compounds and methods of use thereof
ATE284407T1 (de) * 1997-11-07 2004-12-15 Isis Pharmaceuticals Inc Pyrimidinderivate als markierte bindungspartner
DE19838998A1 (de) * 1998-08-27 2000-03-09 Bayer Ag Neue Naturstoffderivate
SE9903894D0 (sv) * 1999-10-28 1999-10-28 New Pharma Research Ab Novel compounds
CA2426187C (en) * 2000-10-18 2011-08-16 Pharmasset Limited Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation
DE10061538A1 (de) * 2000-12-11 2002-06-20 Bayer Ag Ureido-Dihydropyrimidinone
DE10061542A1 (de) * 2000-12-11 2002-06-13 Bayer Ag Alkanoylamino-pyrimidine
HUP0303410A3 (en) * 2000-12-14 2005-12-28 Procter & Gamble Antimicrobial quinolones, pharmaceutical compositions containing them and their use
CA2436665C (en) * 2001-01-29 2012-01-10 Bio-Rad Laboratories, Inc. Nucleic acid derivatives
TWI248936B (en) * 2001-03-21 2006-02-11 Merck Sharp & Dohme Imidazo-pyrimidine derivatives as ligands for GABA receptors
US20030207804A1 (en) * 2001-05-25 2003-11-06 Muthiah Manoharan Modified peptide nucleic acids
EP1499627A2 (en) * 2001-07-03 2005-01-26 ISIS Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
JP4306206B2 (ja) * 2001-09-04 2009-07-29 住友化学株式会社 イミダゾ［１，２−ａ］ピリミジン、その用途およびその製造中間体
GB0205165D0 (en) * 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
WO2004080466A1 (en) * 2003-03-07 2004-09-23 Ribapharm Inc. Cytidine analogs and methods of use
WO2005019228A1 (en) * 2003-08-12 2005-03-03 Achillion Pharmaceuticals, Inc. Isothiazoloquinolones and related compounds as anti-infective agents
KR101272263B1 (ko) * 2005-07-27 2013-06-13 아칠리온 파르마세우티칼스 인코포레이티드 감염 방지제로서 사용되는8-메톡시-9ｈ-이소티아졸로［5,4-ｂ］퀴놀린-3,4-디온 및관련 화합물
WO2007101871A1 (de) * 2006-03-08 2007-09-13 Basf Se Substituierte imidazolopyrimidine, verfahren zu ihrer herstellung und ihre verwendung zur bekämpfung von schadpilzen sowie sie enthaltende mittel
US20100112561A1 (en) * 2006-08-25 2010-05-06 Stefan Lutz Fluorescent nucleoside analogues
EP1964841A1 (en) * 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]azine and their use as pharmaceuticals
KR20090098710A (ko) * 2008-03-14 2009-09-17 주식회사 씨티아이바이오 세포투과성과 핵산 결합력이 좋은 펩타이드 핵산 유도체
CN104628729B (zh) * 2009-10-16 2018-11-06 梅琳塔治疗公司 抗微生物化合物和其制备和使用方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI621439B (zh) * 2009-10-16 2018-04-21 梅林塔療法公司 抗微生物性化合物及其製造與使用方法
US11999739B2 (en) 2016-05-06 2024-06-04 BioVersys AG Antimicrobials methods of making and using the same

Also Published As

Publication number Publication date
CN105646370A (zh) 2016-06-08
SG10201406634VA (en) 2014-11-27
TWI621439B (zh) 2018-04-21
MY161870A (en) 2017-05-15
EA201500913A1 (ru) 2015-12-30
TW201630914A (zh) 2016-09-01
TW201731849A (zh) 2017-09-16
KR101857694B1 (ko) 2018-06-19
SG10201406631TA (en) 2014-11-27
JP2018039784A (ja) 2018-03-15
TW201125564A (en) 2011-08-01
CN104628729A (zh) 2015-05-20
TWI629277B (zh) 2018-07-11
MY165011A (en) 2018-02-28
TW201622725A (zh) 2016-07-01
TW201125566A (en) 2011-08-01
TWI618707B (zh) 2018-03-21
CN107445976A (zh) 2017-12-08
AR080617A1 (es) 2012-04-25
TW201726630A (zh) 2017-08-01
SG10201406635QA (en) 2014-11-27
CN108456211A (zh) 2018-08-28
CN104628729B (zh) 2018-11-06
KR20120099436A (ko) 2012-09-10
TWI612048B (zh) 2018-01-21
TW201124417A (en) 2011-07-16
TW201825495A (zh) 2018-07-16
JP2016121171A (ja) 2016-07-07
JP2016172733A (ja) 2016-09-29
CN107266470A (zh) 2017-10-20
PH12012500732A1 (en) 2020-10-19
JP2018024653A (ja) 2018-02-15
NZ623384A (en) 2016-06-24
JP2016153405A (ja) 2016-08-25
JP2019038808A (ja) 2019-03-14
AR080558A1 (es) 2012-04-18
KR20120099435A (ko) 2012-09-10
AR080559A1 (es) 2012-04-18
NZ713357A (en) 2017-05-26
KR20120101392A (ko) 2012-09-13

Similar Documents

Publication Publication Date Title
KR101972992B1 (ko) 항미생물성 화합물 및 이의 제조 방법 및 사용 방법
TWI589294B (zh) 抗微生物性化合物及其製造與使用方法
US9845297B2 (en) Antimicrobial compounds and methods of making and using the same
US10947237B2 (en) Antimicrobial compounds and methods of making and using the same
TW201305172A (zh) 抗微生物化合物及其製造與使用方法
KR20180051676A (ko) 항미생물성 화합물 및 이의 제조 방법 및 사용 방법
US11999739B2 (en) Antimicrobials methods of making and using the same

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees